Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q4 EPS by 1c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of ($0.55), $0.01 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• HighPeak Energy mulls sale - Reuters
• FAA officials are preparing to launch an AI-powered air-traffic tool in one of the nation’s busiest corridors as soon as Monday - WSJ
• SpaceX Discusses Buying Data For Ai Models From Failed Startups - Bloomberg